This rapid growth in demand for monoclonal antibody production has been well accommodated by the industrialization of mAb manufacturing and analysis. However, the therapeutic efficacy of these antibody drugs might be hampered by their large molecular masses and complex hetero-tetrameric structures. To address these issues and to enhance the overall therapeutic efficiency, it is essential to detect, characterize and quantify impurities as well as the important parameters about structural variants and modifications, affinity, stability, immunogenicity and safety of the final products. This physical truth has been emphasizing the need for innovative and efficient analytic solutions and services.